Discontinued — last reported Q1 '26
Alliance revenue - Lynparza — Sales
Merck & Co. Alliance revenue - Lynparza — Sales decreased by 56.2% to $341.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 45.4%, from $625.00M to $341.00M. Over 4 years (FY 2021 to FY 2025), Alliance revenue - Lynparza — Sales shows an upward trend with a 10.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase reflects strong market demand and effective commercial execution, whereas a decrease suggests potential competitive pressure or declining product lifecycle performance.
Detailed definition
This metric represents the total gross sales generated by a specific pharmaceutical product managed under an alliance or...
Peer comparison
Comparable to total product sales or net product revenue reported by peers for specific therapeutic franchises or partnered assets.
mrk_segment_alliance_revenue_lynparza_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $496.00M | $492.00M | $533.00M | $532.00M | $550.00M | $568.00M | $582.00M | $550.00M | $620.00M | $598.00M | $630.00M | $584.00M | $635.00M | $675.00M | $728.00M | $625.00M | $739.00M | $758.00M | $778.00M | $341.00M |
| QoQ Change | — | -0.8% | +8.3% | -0.2% | +3.4% | +3.3% | +2.5% | -5.5% | +12.7% | -3.5% | +5.4% | -7.3% | +8.7% | +6.3% | +7.9% | -14.1% | +18.2% | +2.6% | +2.6% | -56.2% |
| YoY Change | — | — | — | — | +10.9% | +15.4% | +9.2% | +3.4% | +12.7% | +5.3% | +8.2% | +6.2% | +2.4% | +12.9% | +15.6% | +7.0% | +16.4% | +12.3% | +6.9% | -45.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s alliance revenue - lynparza — sales?
- Merck & Co. (MRK) reported alliance revenue - lynparza — sales of $341.00M in Q1 2026.
- How has Merck & Co.'s alliance revenue - lynparza — sales changed year-over-year?
- Merck & Co.'s alliance revenue - lynparza — sales decreased by 45.4% year-over-year, from $625.00M to $341.00M.
- What is the long-term trend for Merck & Co.'s alliance revenue - lynparza — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s alliance revenue - lynparza — sales has grown at a 10.1% compound annual growth rate (CAGR), from $1.98B to $2.90B.
- What does alliance revenue - lynparza — sales mean?
- Total market sales for a specific pharmaceutical product managed through a partnership.